Patents by Inventor Michael E. Deason

Michael E. Deason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
    Patent number: 6849732
    Abstract: The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: February 1, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Scott E. Zook, Raymond Dagnino, Jr., Michael E. Deason, Steven L. Bender, Michael J. Melnick
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6605721
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: August 12, 2003
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20030135051
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: October 22, 2002
    Publication date: July 17, 2003
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
    Publication number: 20030130506
    Abstract: The invention relates to compounds of the formula 1: 1
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Scott E. Zook, Raymond Dagnino, Michael E. Deason, Steven L. Bender, Michael J. Melnick
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6512135
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: January 28, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
    Patent number: 6500948
    Abstract: The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: December 31, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Scott E. Zook, Raymond Dagnino, Jr., Michael E. Deason, Steven L. Bender, Michael J. Melnick
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20020161236
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: April 2, 2002
    Publication date: October 31, 2002
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Patent number: 6407285
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: June 18, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors
    Publication number: 20020038027
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Application
    Filed: June 26, 2001
    Publication date: March 28, 2002
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Processes for making nelfinavir mesylate
    Patent number: 6303786
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: October 16, 2001
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Metalloproteinase inhibitors and intermediates useful for their preparation
    Patent number: 6153757
    Abstract: The invention relates to compounds of formula (1) ##STR1## wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: November 28, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Scott E. Zook, Raymond Dagnino, Jr., Michael E. Deason, Steven L. Bender, Michael J. Melnick
  • Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
    Patent number: 5962725
    Abstract: HIV protease inhibitors inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds can be prepared by the novel methods of the present invention using the novel inventive compounds and intermediates.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 5, 1999
    Assignees: Agouron Pharmaceuticals, Inc., Japan Tobacco, Inc.
    Inventors: Michael E. Deason, Kathleen R. Whitten
  • Process for preparation of clonidine derivatives
    Patent number: 5684156
    Abstract: A novel process for preparing clonidine derivatives has been discovered which is shorter, less expensive and safer than previously known methods. A new thiourea complex has also been discovered which can be directly cyclized to produce the corresponding heterocyclic product.
    Type: Grant
    Filed: August 31, 1995
    Date of Patent: November 4, 1997
    Inventors: David R. Pierce, William D. Dean, Michael E. Deason
  • Preparation of carbonic anhydrase inhibitors
    Patent number: 5473067
    Abstract: A process for synthesizing carbonic anhydrase inhibitors is disclosed.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: December 5, 1995
    Assignee: Alcon Laboratories, Inc.
    Inventors: William D. Dean, Paul W. Zinke, Steven J. Sproull, Michael E. Deason, Raymond E. Conrow, Anura P. Dantanarayana
  • Preparation of carbonic anhydrase inhibitors
    Patent number: 5424448
    Abstract: A process for synthesizing carbonic anhydrase inhibitors is disclosed.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: June 13, 1995
    Assignee: Alcon Laboratories, Inc.
    Inventors: William D. Dean, Paul W. Zinke, Steven J. Sproull, Michael E. Deason, Raymond E. Conrow, Anura P. Dantanarayana
  • Preparation of carbonic anhydrase inhibitors
    Patent number: 5344929
    Abstract: A process for synthesizing carbonic anhydrase inhibitors is disclosed.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: September 6, 1994
    Assignee: Alcon Laboratories, Inc.
    Inventors: William D. Dean, Paul W. Zinke, Steven J. Sproull, Michael E. Deason, Raymond E. Conrow, Anura P. Dantanarayana